tbuckley/cabot-search huggingface dataset:
Throwback
Authors: Larry C Kravitz
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Desmond Bardon Ronald Alwyne Bowen Gordon Dutton Ernest Hunt Cynthia Mary Illingworth (nee Redhead) Gerald Francis ("Joe") Murnaghan William Phillips Edward Platts Alexander Slessor Kota Seetharama Urala
Authors: M. Marrone, D. Wilkinson, B Dutton, K. Beadle, C. Rees, R. Illingworth, J. Hampson, G. Cameron, R. Platts, T J Thomson, P H R Setty
Journal: BMJ (1999)
THU0056 Expression of Piwi-interacting RNA in Rheumatoid Arthritis
Authors: L. Plestilova, A. Ciurea, C. Kolling, R.E. Gay, J. Vencovský, B.A. Michel, M. Neidhart, S. Gay, A. Jüngel
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Piwi-interacting RNAs (piRNAs, 26-31 nucleotides) are recently described short regulatory RNAs, which build functional complexes with the four argonaute-subfamily members PIWI-like proteins to repress gene expression of retrotransposons. We recently presented that PIWIL4 is highly expressed in RA synovial fibroblasts. <h3>Objectives</h3> The aim of our study here was to analyze the expression of piRNAs (piR-651, piR-823 and piR-4987) which are associated with invasion and proliferation of cancer cells. <h3>Methods</h3> Expression of piRNAs (piR-651, piR-823 and piR-4987) was analyzed by TaqMan RealTime-PCR and normalized to RNU6B and RNU48 in synovial fibroblasts (SF) from rheumatoid arthritis (RA) and osteoarthritis (OA) patients (n=8 each) and in peripheral blood mononuclear cells (PBMC) isolated from patients with RA and from healthy controls (HC, n=8 each). HeLa and HEK293 cell lines served as positive controls. RASF (n=4-8) were stimulated or not for 24 hours with Poly(I:C) (10ug/ml), LPS (100ng/ml) or TNFα (10ng/ml) in combination with IL1β (1ng/ml). PIWIL4 was silenced in RASF (n=5) with siRNA and the expression of piRNAs was analyzed 48h later. <h3>Results</h3> High expression of piR-651, piR-823 and piR-4987 could be detected in both RA and OASF (RA/OA mean dCt= -9.0/-8.9, -4.7/-4.2, 0.8/0.9). A strong expression of piR-651, piR-823 and piR-4987 was also found in PBMC of patients with RA and HC (mean dCt= - 3.4/-3.7, 7.2/7.1, 11.7/12.7). In the cancer cell lines, piR-651, piR-823 and piR-4987 were expressed as follows: HeLa (dCt= -10.2/-3.6/-1.1), HEK293 (dCt= -9.9/-4.9/-1.3). Levels of piR-4987 in RASF were further enhanced by Poly(I:C) (to 3.0-fold, p=0.002) and by LPS (to 3.5-fold, p=0.071), but not by TNFα in combination with IL1β. Expression of piR-651 and piR-823 was not changed neither by Poly(I:C) nor by LPS or TNFα in combination with IL1β. PIWIL4 silencing (to 0.3-fold, p&lt;0.0001) in RASF did not change expression of the piR-651 (to 1.0-fold, p=0.968), piR-823 (to 0.8-fold, p=0.107) or piR-4987 (to 0.8-fold, p=0.075). <h3>Conclusions</h3> We have demonstrated high expression of piR-651, piR-823 and piR-4987 in synovial fibroblasts and PBMC in RA. Levels of those piRNAs in RA are similar to those in OA. The up regulation of piR-4987 after innate immune stimulation suggests a functional role in synovial fibroblasts in RA. <h3>Acknowledgements</h3> OSTEOIMMUNE, IMI-BTCure, EuroTEAM, IAR, MHCR project 023728 <h3>Disclosure of Interest</h3> None declared
ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?
Authors: Stephany Corrêa, Eliana Abdelhay, Peter Paschka, Verena I. Gaidzik, Rocio Hassan, Rainer Claus, Richard F. Schlenk, Konstanze Döhner, Lars Bullinger
Journal: Blood (2014)
AB0342 Serum Transferrin Receptor Ratio to Serum Ferritin and Hepcidin Levels in the Differential Diagnosis of Anemia in Rheumatoid Arthritis Patients
Authors: E. Nita, E. Kyratzopoulou, P. Eliadis, D. Makatsori, C. Kostara, A. Mitsioni, C. Tsaousi, S. Levidiotou, E. Bairaktari, A. Mamalaki, P.V. Voulgari
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Anemia of chronic disease (ACD) is an extra-articular manifestation of rheumatoid arthritis (RA) that is due to proinflammatory stimuli by inhibition of erythropoiesis directly and indirectly by decreasing the iron available for heme synthesis. ACD and iron deficiency anemia (IDA) often occur concurrently and often leads to a diagnostic dilemma. The assessment of the anemia is based on hemoglobin content parameters, serum levels of iron, ferritin, total iron binding capacity (TIBC) and saturation of ferritin, parameters that are often directly affected by inflammation, hindering clinical interpretation. Soluble transferrin receptor (sTfR) levels indicate iron deficiency and are unaffected by inflammation while, sTfR/log ferritin index (sTfR Index) provides an estimate of body iron over a wide range of normal and depleted iron stores. Hepcidin, a liver- derived acute-phase reactant is a key mediator of ACD. <h3>Objectives</h3> The aim of this study is to estimate the ability of hepcidin, sTfR and sTfR/log ferritin index to improve differential diagnosis of ACD and IDA in RA patients <h3>Methods</h3> Serum samples from 38 RA patients (29 women and 9 men) with mean age ± SD 68.79±12.64 years, with anemia (Hb&lt;12 gr/dl for women and Hb&lt;13gr/dl for men) were collected after an overnight fast. Forty healthy individuals, age and gender matched, were used as a control group. Total blood count, conventional biochemical parameters and serum levels of ferritin (ng/ml) and sTfR (nmol/L) were measured according to standard procedures. Serum hepcidin levels were measured using a competitive in-house ELISA developed by our group. The patients with rheumatoid arthritis were divided into two groups according to the levels of sTfR Index. A cutoff value of sTfR/log fer≥14 has been used as prognostic for the presence of IDA. <h3>Results</h3> Patients with RA presented higher levels of hepcidin (59.95±20.79 vs 22.72±10.81 μg/l) and higher levels of sTfR/logfer (23.73±41.4 vs 7.07±2.93) compared to healthy individuals. Patients with sTfR/log fer≥14 presented marginary significantly lower levels of hepcidin (55,95±15,66 μg/l) than patients with sTfR/log fer&lt;14 (61,17±23,77 mg/L). <h3>Conclusions</h3> These results indicate that hepcidin levels can enhance the distinctive role of StfR/logFer index leading to a better and safer distinction of RA anemic patients with IDA, IDA+ACD or ACD. <h3>Acknowledgements</h3> This work was supported by grant from the Greek General Secretariat of Research and Technology 09SYN-12-682 <h3>Disclosure of Interest</h3> None declared
FRI0292 Osteoporosis –A Risk Factor for Cardiovascular Diseases (A Follow-Up Study)
Authors: I. Tasić, M. Rašić Popović, S. Stojanović, B. Stamenković, S. Kostić, V. Skakić, D.P. Dejan Popović, G. Lazarević, D. Bogdanović, V. Stefanović
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Cardiovascular (CV) diseases and bone fractures due to osteoporosis are the leading causes of death in the elderly. <h3>Objectives</h3> The aim of this study was to demonstrate a correlation between the overall risk for CV events, and low bone density in postmenopausal women, and its impact on the incidence of serious CV events. <h3>Methods</h3> Our prospective study involved 300 postmenopausal women. All the examinees were divided into three groups based on their measured bone density: Group I – 84 examinees with osteoporosis; Group II – 115 examinees with osteopenia; and Group III – 101 examinees with normal bone density. In all examinees the overall ten-year risk for a fatal CV event was calculated using the SCORE system tables. <h3>Results</h3> After a 36-month follow-up, CV events occurred in 19 (6.3%) examinees. Significant differences in the incidence of CV events were demonstrated between the patients with osteoporosis, osteopenia, and normal bone density (χ2=28.7; p&lt;0.001), as well as between those with a high and low CV risk (χ2=22.6; p&lt;0.001). Multivariate logistic regression analysis showed that smoking (OR: 2.23; 95% CI: 1.02 to 6.19; p=0.035), and increase of overall CV score (OR: 1.36; 95% CI: 1.17 to 1.58; p&lt;0.001) are associated with increased CV event risk, while the increase of T score value is associated with decreased risk of CV event (OR: 0.42; 95% CI: 0.25 to 0.73; p=0.002). <h3>Conclusions</h3> Measurement of bone density with a standard assessment of the total CV risk could be useful for selecting women who need intensive prevention and treatment of atherosclerosis. <h3>Disclosure of Interest</h3> None declared
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia
Authors: Seongseok Yun, Nicole D. Vincelette, Ivo Abraham
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PWE-377 Pitfalls in piecemeal resection of complex colorectal polyps
Authors: ZP Tsiamoulos, T Elliott, N Suzuki, P Bassett, BP Saunders
Journal: Gut (2015)

<h3>Introduction</h3> The role of piecemeal endoscopic mucosal resection (p-EMR) for sessile/flat colonic polyps previously destined for surgery is expanding. However, surgery remains appropriate in some cases. The objectives of this study were to determine the primary reasons in this decision-making, and factors associated with polyp non-excision, and the presence of submucosal invasive cancer (SMIC). <h3>Method</h3> A prospective observational cohort study of all polyps referred for consideration of p-EMR to our tertiary centre between January 2010 and August 2012 was performed. For each case, a detailed endoscopic evaluation of the polyp was performed prior to the polyp being excised or not excised. The primary reason for polyp non-excision was documented. Univariable and multivariable analyses were performed to determine factors associated with (i) non-excision and (ii) submucosal invasive cancer (SMIC). <h3>Results</h3> Seventy-one of 419 (17%) polyps were not excised (p-EMR not attempted in 52/71 and abandoned in 19/71 cases). The primary reasons for non-excision were; suspected SMIC (36/71), polyp size +/- location, poor polyp access and patient comorbidities. On multivariate analysis, factors associated with polyp non-excision were increasing polyp size (p &lt; 0.001), site (caecum and sigmoid colon, p &lt; 0.001), surface features suggestive of SMIC (Paris IIc, Kudo V and NICE III, all p &lt; 0.001) and female gender (p = 0.04). SMIC was present in 9% of polyps &gt;2cm and was more prevalent in the rectum to the descending colon than in the transverse colon to caecum (p = 0.04). Although surface features were associated with SMIC on univariable analysis and the positive predictive values are relatively high (Paris IIc 80%, Kudo V 86% and NICE III 86%)., the sensitivity of these features for a diagnosis of SMIC were relatively low (Paris IIc 11%, Kudo V 49% and NICE III 51%). <h3>Conclusion</h3> A percentage of polyps referred to a tertiary institution were not suitable for p-EMR, most commonly because of suspicion of SMIC. Specific surface features of malignancy may be present but the physician’s overall endoscopic evaluation was also useful in predicting suitability of polyps for p-EMR. <h3>Disclosure of interest</h3> None Declared.
Let's re-examine these MTX points once again
Authors: J M Kremer
Journal: Annals of the Rheumatic Diseases (2016)

Duran et al may have missed my point. If so, this is my fault in that I must not have made it clearly enough. I detected a clear implication of industry bias in the thrust and premise of their findings. To support this position, they extrapolate from studies which purport to illustrate the wisdom of the implications of their review. They correctly point out that one of the references I quoted in the editorial1 on methotrexate (MTX) folate single-nucleotide polymorphisms (SNPs) leading to different outcomes employed higher doses of MTX and there was little difference in reported toxicity between …
DNA methylation signature to identify treatment response in triple negative breast cancer.
Authors: Begona Pineda, Angel Diaz-Lagares, Jose Alejandro Perez-Fidalgo, Elisa Alonso, Juan Sandoval, Ines Gonzalez, Ana-Belen Crujeiras, Octavio Burgues, Manel Esteller, Ana Lluch, Pilar Eroles
Journal: Journal of Clinical Oncology (2015)

1079 Background: The triple negative breast cancer (TNBC) subtype is an aggressive phenotype with scarce treatment alternatives. Chemotherapy (CT) is only effective in about 40% of patients. DNA methylation could play a role in this differential response between TNBC. The objective of our work was to define a DNA methylation profile with potential to predict response to CT in TNBC patients. Methods: Tumor samples from patients diagnosed with a TNBC stage I to III and considered candidate for neoadjuvant CT with anthracycline and taxane were identified. DNA was extracted from FFPA samples obtained by pre-surgery biopsy. Patients were classified according to residual cancer burden (RCB) index in responders (RCB = 0, n = 10) vs. non-responders (RCB > 0, n = 14). DNA methylation was performed by the Infinium HumanMethylation450 array (Illumina) that allows interrogating more than 485,000 methylation CpG sites per sample. The selection criteria were: p < 0.05 and mean difference between methylation groups of ≥ 20%. The functions associated to genes were analyzed using the Gene Ontology FDR. Results: We identified 24 samples from TNBC patients. Median age was 58.4 (48.5-69.0) years. Most patients presented T1-2 tumors (72%), no axillar lymph involvement (53%). Proliferative scores were high with 53% of patients with ki67 > 60% and 88% of grade 3 tumors. We have detected 133 differentially methylated CpGs allowing clearly separate the responders from the non-responders. Thirty five were located at CpG islands (CGIs) or CGI shores at promoter regions. We selected 11 CpGs corresponding to 11 genes with the less variation intragroup (standard deviation ≤ 20%). Nine of them showed a consistent DNA methylation profile of consecutive CpGs. Of these, 5 genes (genes 1 to 5) increased and 4 genes (genes 6 to 9) decreased methylation in non-responding patients compared to those who responded to treatment. The increase ratio varies between 0.20 and 0.27, and the decrease ranges between -0.21 and -0.22. Some of these genes were related to Wnt and Hedgehog pathways, epithelial-mesenchymal transition and cell migration. Conclusions: DNA methylation profile is an interesting predictive tool for response to neoadjuvant CT in TNBC.
Transplantation Immunology
Authors: Fritz H. Bach, David H. Sachs
Journal: New England Journal of Medicine (1987)

The MHC is of overwhelming importance in determining the fate of an allograft. Over the past 10 years, our understanding of the serology of this locus, its role in cellular immunity, its biochemistry, and most recently, its molecular biology has increased enormously. Genes for all the known loci, both Class I and Class II, have been cloned and sequenced, and their evolution and function are therefore now more amenable to investigation at the molecular level. Concomitantly, an understanding of the different populations of immune cells involved in the recognition of the antigens encoded by these loci has permitted a more precise immunologic description of the rejection response. It is now clear that recognition of both Class I and Class II allogeneic differences by both helper and cytotoxic T cells has an important role in graft rejection. The goal of transplantation biologists is to take advantage of this increased understanding in order to design new techniques for specifically modifying the immune response to MHC antigens and achieving specific tolerance. Some exciting approaches are already being studied, including specific modifications of both the antigen and the receptor arms of the immune response. It is hoped that these approaches will have new clinical applications in the near future.
FRI0312 Relationship Between Synovial Inflammation and Ultrasound Urate Deposits in Patients with Gout: Table 1
Authors: F. Perez-Ruiz, E. Garmendia, I. Urionagüena, S.P. Chinchilla
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Urate intra-articular deposits are seen in ultrasound as double contour sign (DCS), hyperechogenic aggregates and tophi, but their separate contribution to synovial inflammation has yet to be determined. <h3>Objectives</h3> To evaluate the association between DCS and tophi with the presence of synovial inflammation in ultrasound examination. <h3>Methods</h3> Patients with crystal-proven gout were to be consecutively included, and had to be asymptomatic for at least 4 years (free of episodes of acute inflammation). They were recruited from two cohorts of prospective follow-up, one on active treatment and the other after withdrawal of urate-lowering therapy. Ultrasound of the 1st metatarsophalangeal joint (1st MTP) and of the non-dominant knee was performed by an explorer who was blinded for clinical data. The DCS was described as absent or present in less or more than 50% of the synovial surface. On the knee, the DCS location was registered as present in one or both femoral condyles. The presence of tophi was evaluated as hyperechogenic aggregates of at least 5mm maximum diameter, with a hypoechogenic halo associated. Synovial inflammation was evaluated by the measurement of synovial thickening with a semi-quantitative scale (0-3) and Power-Doppler (PD) semi-quantitative scale (0-3). Bi-variable and multiple regression analysis were made. <h3>Results</h3> Ultrasound evaluation was proposed to 100 consecutive patients who fulfilled criteria, none on colchicine, NSAID or corticosteroid; of which 88 agreed to participate or attended the appointment. All of them were male, with a median age of 57±9 years, 74% with previous involvement of 1st MTP joint and 59% of the examined knee. Thirteen patients were excluded from analysis due to the presence of ultrasonographic chondrocalcinosis in the knee. The frequency of deposits in both cohorts was not different, thus a pooled analysis was conducted. The descriptive findings are presented in the table: Multiple regression analysis showed that the presence of synovitis &gt;0 was only statistically associated in the 1st MTP to tophi (R<sup>2</sup> 0.31), and in the knee to the presence of extense or bilateral DCS and tophi (R<sup>2</sup> 0.28). The PD&gt;0 signal was only associated in both 1st MTP and in knee to tophi (R<sup>2</sup> 0.25 and 0.18). The more restrictive analysis of synovitis&gt;1 and PD&gt;1 did not show changes in the results. <h3>Conclusions</h3> Ultrasonographic urate deposits are associated to synovitis or active synovitis (intra-articular synovitis with PD signal) as markers of synovial inflammation. The presence of tophi is the main factor associated, so the resolution of the intra-articular tophi seems to be the principal therapeutic goal. <h3>Acknowledgements</h3> The study was funded by Asociacion de Reumatologos del Hospital de Cruces. <h3>Disclosure of Interest</h3> None declared
Stimulation of Growth of a Transplantable Hepatoma in Rats by Parenteral Nutrition 2
Authors: Ivan L. Cameron, William A. Pavlat
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Stimulation of Growth of a Transplantable Hepatoma in Rats by Parenteral Nutrition Get access Ivan L. Cameron, Ivan L. Cameron Search for other works by this author on: Oxford Academic PubMed Google Scholar William A. Pavlat William A. Pavlat 3Department of Anatomy, The UniverSity of Texas Health Science Center at San Antonio, 7703. Floyd Curl Drive, San Antonio, Texas 78284. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 3, March 1976, Pages 597–602, https://doi.org/10.1093/jnci/56.3.597 Published: 01 March 1976 Article history Received: 17 July 1975 Accepted: 23 September 1975 Published: 01 March 1976